RYZB Stock Recent News
RYZB LATEST HEADLINES
After navigating treacherous waters in the preceding year, the US initial public offering (IPO) market embarked on a path of recovery in 2023, signaling the inception of a new upcycle.
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a biopharmaceutical company developing an innovative radiopharmaceutical pipeline to treat different cancers, today announced that members of the Company's management team will participate in the following investor conferences in November 2023:
Initiating RayzeBio, Inc. coverage with a Buy rating and common stock price target of $43 based on my risk-adjusted NPV discounted cash flow model, representing a 110% upside. The company's radiopharmaceutical technology could revolutionize the cancer treatment landscape. RYZ801 has shown promise in GPC3 expressing hepatocellular cancers.